$ADCT News
Last published 3d ago
- 3d agoADCTADC Therapeutics SA - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3d agoADCTADC Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational UpdatesPR NewswireADC Therapeutics SA (NYSE: ADCT) today reported full financial results for the third quarter ended September 30, 2026, and provided recent...
- 1w agoADCTGenmab's Third Quarter 2026 Financial Results - ADC THERAPEUTICS SAEarnings Call TranscriptsHello and welcome to the GenMAP 3rd Quarter 2026 Financial Results Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking state
- 1w agoADCTADC Therapeutics SA - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 8.01 Item 9.01
- 2w agoADCTADC Therapeutics Announces ZYNLONTA® Updates in JapanPR NewswireLicensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese Phase 1/2 clinical resultsTanabe Pharma entered into exclusive
- 1mo agoADCTADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure ImprovementsPR Newswire$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Royalty financing agreement amended, removing change-of-control
- 1mo agoADCTGenmab Morgan Stanley 24th Annual Global Healthcare Conference - ADC THERAPEUTICS SAEarnings Call TranscriptsThis session at the Morgan Stanley Global Healthcare Conference, we're very excited to have the team from GENMAB, Jan and Tayi, with us. Let me just get through a quick disclosure. For important disclosures, please see t
- 1mo agoADCTGenmab Morgan Stanley 24th Annual Global Healthcare Conference - ADC THERAPEUTICS SAEarnings Call TranscriptsThis session at the Morgan Stanley Global Healthcare Conference, we're very excited to have the team from GENMAB, Jan and Tayi, with us. Let me just get through a quick disclosure. For important disclosures, please see t
- 2mo agoADCTWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - ADC THERAPEUTICS SAEarnings Call TranscriptsOkay, so we're ready for our next panel. I have here with me today Judith, CBO of GenMap. Thanks so much for joining us. Thank you for having me. Perfect. So maybe we can start with, you know, kind of introductory questi
- 2mo agoADCTADC Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferencePR NewswireADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor...
- 3mo agoADCTADC Therapeutics Q2 2026 Earnings - ADC THERAPEUTICS SAEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q2 2026 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer
- 3mo agoADCTADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational UpdatesPR NewswireSecond quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASHCompany evaluating regulatory
- 3mo agoADCTADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026PR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 4mo agoADCTADC Therapeutics Announces New Employee Inducement GrantPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 4mo agoADCTADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination TrialPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the...
- 4mo agoADCTADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory PrioritiesPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a...
- 5mo agoADCTADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell LymphomaPR NewswireADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab...
- 6mo agoADCTADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdatesPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported...
- 6mo agoADCTADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 6mo agoADCTADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026PR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 7mo agoADCTADC Therapeutics Announces New Employee Inducement GrantPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 8mo agoADCTADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational UpdatePR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported...
- 8mo agoADCTADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026PR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 8mo agoADCTADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 8mo agoADCTADC Therapeutics to Participate in March Investor ConferencesPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
- 8mo agoADCTADC Therapeutics Announces Amended HealthCare Royalty Financing AgreementPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 9mo agoADCTADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 9mo agoONCYABBVGMABADCT+1$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command PremiumPR NewswireThe oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This...
- 10mo agoADCTADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate UpdatesPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today provided...
- 10mo agoADCTADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferencePR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 10mo agoADCTADC Therapeutics Announces New Employee Inducement GrantPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 10mo agoGTBPADCTSTROCRNX+1Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma PipelinesPR NewswireEquity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning...
- 11mo agoADCTADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell LymphomaPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
- 11mo agoADCTADC Therapeutics to Provide Update on LOTIS-7 Clinical TrialPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 11mo agoADCTADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 1y agoADCTADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational UpdatePR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported...
- 1y agoADCTADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025PR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 1y agoADCTADC Therapeutics to Present at November Investor ConferencesPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
- 1y agoADCTADC Therapeutics Announces $60 Million Private PlacementPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 1y agoADCTADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 1y agoADCTADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 1y agoADCTADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025PR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 1y agoADCTADC Therapeutics SA (ADCT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoADCTADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational UpdatePR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported...
- 1y agoADCTADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025PR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 1y agoADCTADC Therapeutics Makes Grants to New Employees Under Inducement PlanPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 1y agoADCTADC Therapeutics Makes Grant to New Employee Under Inducement PlanPR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
- 1y agoONCYTEVACTORADCT+1The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?PR NewswireUSA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in...
- 1y agoADCTADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)PR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
- 1y agoADCTADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028PR NewswireADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...